Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3944106 | 0.95 | KMT2A (0.53) | S1PR1KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL3888340 | 0.93 | S1PR1 (0.59) | S1PR1KMT2ASMN1; SMN2TP53MAPT | |
| SCHEMBL4520894 | 0.93 | KMT2A (0.56) | S1PR1KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL3952157 | 0.93 | S1PR1 (0.57) | S1PR1KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL3945831 | 0.93 | CACNA1B (0.52) | S1PR1KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL4515009 | 0.92 | S1PR1 (0.59) | S1PR1KMT2AALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL4041962 | 0.92 | SMN1; SMN2 (0.51) | S1PR1KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL3949029 | 0.92 | S1PR1 (0.58) | S1PR1KMT2ATP53MAPTRXFP1 | |
| SCHEMBL3945897 | 0.91 | KMT2A (0.52) | S1PR1KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL3946605 | 0.91 | S1PR1 (0.57) | S1PR1KMT2AALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318546-A1 | Chromen-2-One Derivatives | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | claimed |
| EP-2010511-A1 | CHROMEN-2-ONE DERIVATIVES | Novartis AG (CH) | 2009-01-07 | — | — | EP | claimed |
| WO-2007115820-A1 | CHROMEN-2-ONE DERIVATIVES | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318546-A1 | Chromen-2-One Derivatives | CYP1A2, CYP4B1, CYP1B1 | S1PR1 3084/4885KMT2A 2272/4885ALDH1A1 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.